Congress Materials - Psych Congress 2025
2025 Psych Congress | Sep 17-21 | San Diego, CA
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Characteristics and Clinical Outcomes of Patients with Treatment-Resistant Depression Completing Esketamine Intranasal Spray Induction Phase in the Veterans Health Administration
This poster will be available after Sep 17 2025
Comparison of Real-world Response and Remission among Patients with Treatment-Resistant Depression Treated with Esketamine Nasal Spray or Antipsychotic Augmentation
This poster will be available after Sep 17 2025
Effect of Esketamine Nasal Spray Monotherapy on Emotional Blunting in Adult Patients With Treatment-Resistant Depression: A Post Hoc Analysis
This poster will be available after Sep 17 2025
Efficacy and Safety of Esketamine Nasal Spray as Monotherapy in Adult Patients With Treatment-Resistant Depression for up to 4 Months of Treatment: A Post Hoc Analysis
This poster will be available after Sep 17 2025
Efficacy of Lumateperone 42 mg in the Treatment of Major Depressive Disorder: A Pooled Analysis of Phase 3 Randomized Controlled Trials
This poster will be available after Sep 17 2025
Long-Term Adjunctive Lumateperone Treatment in Major Depressive Disorder: Results From a Six-Month Open-Label Extension Study
Suresh Durgam, Willie R. Earley, Susan G. Kozauer, Changzheng Chen, Tobie Escher, Andrew J. Cutler
This poster will be available after Sep 17 2025
Long-Term Safety and Efficacy of Esketamine Nasal Spray After A Lapse in Maintenance Treatment: A Post Hoc Analysis of the SUSTAIN-3 Study
This poster will be available after Sep 17 2025
Long-Term Safety and Efficacy of Esketamine Nasal Spray as Monotherapy: A Post Hoc Analysis of the SUSTAIN-3 Study
This poster will be available after Sep 17 2025
Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder and Anxious Distress
This poster will be available after Sep 17 2025
Lumateperone for the Prevention of Relapse in Patients with Schizophrenia: Results From a Double-Blind, Placebo-Controlled, Randomized Withdrawal, Phase 3 Trial
This poster will be available after Sep 17 2025
Lumateperone Treatment for Major Depressive Episodes with Mixed Features in Major Depressive Disorder and Bipolar I or Bipolar II Disorder: A Post Hoc Analysis of Anhedonia
This poster will be available after Sep 17 2025
Montgomery-ÅsbergDepression Rating Scale Anhedonia Factor Score Following Esketamine Nasal Spray Monotherapy in Adult Patients With Treatment-Resistant Depression: A Post Hoc Analysis
This poster will be available after Sep 17 2025
Response and remission on esketaminenasal spray in patients with treatment-resistant depression overall and among subgroup of TMS-naïve
This poster will be available after Sep 17 2025
Safety and Tolerability of Lumateperone 42 mg for the Adjunctive Treatment of Major Depressive Disorder: A Pooled Analysis of 2 Randomized Placebo-Controlled Trials
This poster will be available after Sep 17 2025
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
